Oprelvekin is a recombinant human interleukin 11, produced by recombinant DNA technology using E.coli. It has a molecular weight of approximately 19.0kD, non-glycosylated. The polypeptide is 177 amino acids and differs from the 178 amino acid length of native IL-11 only in lacking the amino-terminal protein residue, this alteration has not resulted in measurable differences in bioactivity either in vitro or in vivo.
Oprelvekin is indicated for severe thrombocytopenia with degree III and IV induced by chemotherapy to solid tumor and to non-marrow leukemia. It could be administered together with rHuG-CSF to treat patients with leucopenia.
Sterile and white lyophilized powder to be reconstituted with a diluent (Sterile Water for Injection)for injection, presented in vials.
Dosage: 1mg/vial, 1.5mg/vial, 2mg/vial, 3mg/vial and 5mg/vial
Reference: Internal Standard
Specific activity: ≥8.0×106U/mg
Purity (HPLC, SDS-PAGE): ≥98%
Active ingredients: Oprelvekin (rHuIL-11)
Inactive ingredients: Glycine, Dibasic Sodium Phosphate and Monobasic Sodium Phosphate.
lShelf life andstorage conditions
Storage at 2
Drug Substance (Concentrated solution)
Storage at -70